Cover Image
市場調查報告書

Les Laboratoires Servier SAS:產品平台分析

Les Laboratoires Servier SAS - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253719
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
Les Laboratoires Servier SAS:產品平台分析 Les Laboratoires Servier SAS - Product Pipeline Review - 2016
出版日期: 2016年03月31日 內容資訊: 英文 60 Pages
簡介

Les Laboratoires Servier SAS是總公司設立於法國的獨立型研究型製藥企業。從事心血管系統疾病和中樞神經系統疾病,糖尿病,癌症,肌肉骨骼及關節疾病治療藥方面的治療藥研究開發、製造與銷售。

本報告提供Les Laboratoires Servier SAS 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,及最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Les Laboratoires Servier SAS 基本資料

  • Les Laboratoires Servier SAS 概要
  • 主要資訊
  • 企業資料

Les Laboratoires Servier SAS :R&D概要

  • 主要的治療範圍

Les Laboratoires Servier SAS :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Les Laboratoires Servier SAS :開發中產品概況

  • 後期階段產品開發中產品
    • 申請登記前的產品/聯合治療模式
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Les Laboratoires Servier SAS :藥物簡介

  • (perindopril + amlodipine besylate)
  • gevokizumab
  • ivabradine
  • lucitanib
  • S-38844
  • S-47445
  • S-49076
  • S-055746
  • Small Molecule to Inhibit Mcl-1 for Cancer
  • Drugs to Inhibit Insulin-Regulated AminoPeptidase for Alzheimer's Disease
  • Monoclonal Antibodies for Cancer
  • Drugs for Breast Cancer

Les Laboratoires Servier SAS :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Les Laboratoires Servier SAS :最新的開發平台資訊

Les Laboratoires Servier SAS :開發暫停中的計劃

Les Laboratoires Servier SAS :開發中止的開發中產品

  • 開發中止的開發中產品簡介

Les Laboratoires Servier SAS :企業理念

Les Laboratoires Servier SAS :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08016CDB

Summary

Global Markets Direct's, 'Les Laboratoires Servier SAS - Product Pipeline Review - 2016', provides an overview of the Les Laboratoires Servier SAS's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Les Laboratoires Servier SAS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Les Laboratoires Servier SAS
  • The report provides overview of Les Laboratoires Servier SAS including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Les Laboratoires Servier SAS's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Les Laboratoires Servier SAS's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Les Laboratoires Servier SAS's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Les Laboratoires Servier SAS
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Les Laboratoires Servier SAS's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Bristol-Myers Squibb Company Snapshot
    • Bristol-Myers Squibb Company Overview
    • Key Information
    • Key Facts
  • Bristol-Myers Squibb Company - Research and Development Overview
    • Key Therapeutic Areas
  • Bristol-Myers Squibb Company - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Bristol-Myers Squibb Company - Pipeline Products Glance
  • Bristol-Myers Squibb Company - Late Stage Pipeline Products
  • Bristol-Myers Squibb Company - Clinical Stage Pipeline Products
  • Bristol-Myers Squibb Company - Early Stage Pipeline Products
  • Bristol-Myers Squibb Company - Drug Profiles
    • nivolumab
    • daclatasvir dihydrochloride + asunaprevir
    • abatacept
    • apixaban
    • beclabuvir hydrochloride
    • brivanib alaninate
    • ipilimumab
    • ulocuplumab
    • BMS-394136
    • BMS-754807
    • BMS-833923
    • BMS-919373
    • BMS-986020
    • BMS-986036
    • BMS-986142
    • CXL-1427
    • dasatinib
    • lirilumab
    • lulizumab pegol
    • Recombinant Protein to Antagonize Fibroblast Growth Factor Receptor for Fibrosis
    • urelumab
    • BMS-986004
    • BMS-986012
    • BMS-986016
    • BMS-986089
    • BMS-986148
    • BMS-986156
    • BMS-986158
    • TD-139
    • Antibody to Target CD40 Ligand for Immunology
    • Biologic to Inhibit PD-L1 for Immunology
    • BMS-262084
    • BMS-777607
    • BMS-813160
    • BMS-906024
    • BMS-963272
    • BMS-986090
    • BMS-986104
    • BMS-986115
    • BMS-986120
    • BMS-986141
    • BMS-986147
    • BMS-986165
    • BMS-986168
    • BMS-986171
    • BMS-986186
    • FLX-925
    • KOS-1803
    • Recombinant Protein 1 to Antagonize Fibroblast Growth Factor Receptor for Fibrosis
    • Small Molecule for Oncology
    • Small Molecule to Antagonize PAR4 for Thromboembolic Disorders
    • Small Molecule to Inhibit BTK for Immunology
    • Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity
    • Small Molecule to Inhibit TYK2 for Immunology
    • BMS-817378
    • ALB-109780
    • AMR-2
    • ARX-720
    • BMS-457
    • BMS-593214
    • BMS-654457
    • BMS-751324
    • BMS-795311
    • BMS-816106
    • BMS-869780
    • BMS-871
    • BMS-884775
    • BMS-986177
    • BMS-986195
    • BMS-986205
    • CXL-1036
    • Drug for Metabolic Disorders
    • Drugs to Agonize FPR-2 for Inflammation
    • DT-1154
    • F-001287
    • NP-11948
    • Small Molecule 2 to Inhibit Factor XIa for Thrombosis
    • Small Molecule for Pulmonary Arterial Hypertension
    • Small Molecule to Activate Kv7.2 for Neuropathic Pain and Diabetic Neuropathy
    • Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity
    • Small Molecule to Antagonize NK1R and Block SERT for Depression
    • Small Molecule to Inhibit IAP for Melanoma
    • Small Molecule to Inhibit NS5B for Hepatitis C
    • Small Molecule to Inhibit XIAP and c-IAP for Melanoma
    • Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease
    • Small Molecules to Inhibit ROR-Gamma for Inflammation
    • Monoclonal Antibody Conjugates for Oncology
    • Proteins for Immunology and Oncology
    • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia
    • Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine
    • Small Molecules to Antagonize CCR2
    • Small Molecules to Inhibit IDO and TDO for Oncology
    • Small Molecules to Inhibit IDO for Oncology
    • Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases
    • Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders
    • Small Molecules to Inhibit TDO for Oncology
  • Bristol-Myers Squibb Company - Pipeline Analysis
    • Bristol-Myers Squibb Company - Pipeline Products by Target
    • Bristol-Myers Squibb Company - Pipeline Products by Route of Administration
    • Bristol-Myers Squibb Company - Pipeline Products by Molecule Type
    • Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action
  • Bristol-Myers Squibb Company - Recent Pipeline Updates
  • Bristol-Myers Squibb Company - Dormant Projects
  • Bristol-Myers Squibb Company - Dormant Projects
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Bristol-Myers Squibb Company - Company Statement
  • Bristol-Myers Squibb Company - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Bristol-Myers Squibb Company - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bristol-Myers Squibb Company, Key Information
  • Bristol-Myers Squibb Company, Key Facts
  • Bristol-Myers Squibb Company - Pipeline by Indication, 2016
  • Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016
  • Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Bristol-Myers Squibb Company - Pre-Registration, 2016
  • Bristol-Myers Squibb Company - Filing rejected/Withdrawn, 2016
  • Bristol-Myers Squibb Company - Phase III, 2016
  • Bristol-Myers Squibb Company - Phase II, 2016
  • Bristol-Myers Squibb Company - Phase I, 2016
  • Bristol-Myers Squibb Company - IND/CTA Filed, 2016
  • Bristol-Myers Squibb Company - Preclinical, 2016
  • Bristol-Myers Squibb Company - Discovery, 2016
  • Bristol-Myers Squibb Company - Pipeline by Target, 2016
  • Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016
  • Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016
  • Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2016
  • Bristol-Myers Squibb Company - Recent Pipeline Updates, 2016
  • Bristol-Myers Squibb Company - Dormant Developmental Projects,2016
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2016
  • Bristol-Myers Squibb Company, Other Locations
  • Bristol-Myers Squibb Company, Subsidiaries
  • Bristol-Myers Squibb Company, Key Manufacturing Facilities

List of Figures

  • Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2016
  • Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016
  • Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2016
  • Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016
  • Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016
  • Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2016

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Bristol-Myers Squibb Company Snapshot
  • Bristol-Myers Squibb Company Overview
  • Key Information
  • Key Facts
  • Bristol-Myers Squibb Company - Research and Development Overview
  • Key Therapeutic Areas
  • Bristol-Myers Squibb Company - Pipeline Review
  • Pipeline Products by Stage of Development
  • Pipeline Products - Monotherapy
  • Pipeline Products - Combination Treatment Modalities
  • Pipeline Products - Partnered Products
  • Pipeline Products - Out-Licensed Products
  • Bristol-Myers Squibb Company - Pipeline Products Glance
  • Bristol-Myers Squibb Company - Late Stage Pipeline Products
  • Bristol-Myers Squibb Company - Clinical Stage Pipeline Products
  • Bristol-Myers Squibb Company - Early Stage Pipeline Products
  • Bristol-Myers Squibb Company - Drug Profiles
  • nivolumab
  • daclatasvir dihydrochloride + asunaprevir
  • abatacept
  • apixaban
  • beclabuvir hydrochloride
  • brivanib alaninate
  • ipilimumab
  • ulocuplumab
  • BMS-394136
  • BMS-754807
  • BMS-833923
  • BMS-919373
  • BMS-986020
  • BMS-986036
  • BMS-986142
  • CXL-1427
  • dasatinib
  • lirilumab
  • lulizumab pegol
  • Recombinant Protein to Antagonize Fibroblast Growth Factor Receptor for Fibrosis
  • urelumab
  • BMS-986004
  • BMS-986012
  • BMS-986016
  • BMS-986089
  • BMS-986148
  • BMS-986156
  • BMS-986158
  • TD-139
  • Antibody to Target CD40 Ligand for Immunology
  • Biologic to Inhibit PD-L1 for Immunology
  • BMS-262084
  • BMS-777607
  • BMS-813160
  • BMS-906024
  • BMS-963272
  • BMS-986090
  • BMS-986104
  • BMS-986115
  • BMS-986120
  • BMS-986141
  • BMS-986147
  • BMS-986165
  • BMS-986168
  • BMS-986171
  • BMS-986186
  • FLX-925
  • KOS-1803
  • Recombinant Protein 1 to Antagonize Fibroblast Growth Factor Receptor for Fibrosis
  • Small Molecule for Oncology
  • Small Molecule to Antagonize PAR4 for Thromboembolic Disorders
  • Small Molecule to Inhibit BTK for Immunology
  • Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity
  • Small Molecule to Inhibit TYK2 for Immunology
  • BMS-817378
  • ALB-109780
  • AMR-2
  • ARX-720
  • BMS-457
  • BMS-593214
  • BMS-654457
  • BMS-751324
  • BMS-795311
  • BMS-816106
  • BMS-869780
  • BMS-871
  • BMS-884775
  • BMS-986177
  • BMS-986195
  • BMS-986205
  • CXL-1036
  • Drug for Metabolic Disorders
  • Drugs to Agonize FPR-2 for Inflammation
  • DT-1154
  • F-001287
  • NP-11948
  • Small Molecule 2 to Inhibit Factor XIa for Thrombosis
  • Small Molecule for Pulmonary Arterial Hypertension
  • Small Molecule to Activate Kv7.2 for Neuropathic Pain and Diabetic Neuropathy
  • Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity
  • Small Molecule to Antagonize NK1R and Block SERT for Depression
  • Small Molecule to Inhibit IAP for Melanoma
  • Small Molecule to Inhibit NS5B for Hepatitis C
  • Small Molecule to Inhibit XIAP and c-IAP for Melanoma
  • Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease
  • Small Molecules to Inhibit ROR-Gamma for Inflammation
  • Monoclonal Antibody Conjugates for Oncology
  • Proteins for Immunology and Oncology
  • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia
  • Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine
  • Small Molecules to Antagonize CCR2
  • Small Molecules to Inhibit IDO and TDO for Oncology
  • Small Molecules to Inhibit IDO for Oncology
  • Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases
  • Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders
  • Small Molecules to Inhibit TDO for Oncology
  • Bristol-Myers Squibb Company - Pipeline Analysis
  • Bristol-Myers Squibb Company - Pipeline Products by Target
  • Bristol-Myers Squibb Company - Pipeline Products by Route of Administration
  • Bristol-Myers Squibb Company - Pipeline Products by Molecule Type
  • Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action
  • Bristol-Myers Squibb Company - Recent Pipeline Updates
  • Bristol-Myers Squibb Company - Dormant Projects
  • Bristol-Myers Squibb Company - Dormant Projects
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Bristol-Myers Squibb Company - Company Statement
  • Bristol-Myers Squibb Company - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Bristol-Myers Squibb Company - Key Manufacturing Facilities
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Bristol-Myers Squibb Company, Key Information
  • Bristol-Myers Squibb Company, Key Facts
  • Bristol-Myers Squibb Company - Pipeline by Indication, 2016
  • Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016
  • Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Bristol-Myers Squibb Company - Pre-Registration, 2016
  • Bristol-Myers Squibb Company - Filing rejected/Withdrawn, 2016
  • Bristol-Myers Squibb Company - Phase III, 2016
  • Bristol-Myers Squibb Company - Phase II, 2016
  • Bristol-Myers Squibb Company - Phase I, 2016
  • Bristol-Myers Squibb Company - IND/CTA Filed, 2016
  • Bristol-Myers Squibb Company - Preclinical, 2016
  • Bristol-Myers Squibb Company - Discovery, 2016
  • Bristol-Myers Squibb Company - Pipeline by Target, 2016
  • Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016
  • Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016
  • Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2016
  • Bristol-Myers Squibb Company - Recent Pipeline Updates, 2016
  • Bristol-Myers Squibb Company - Dormant Developmental Projects,2016
  • Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2016
  • Bristol-Myers Squibb Company, Other Locations
  • Bristol-Myers Squibb Company, Subsidiaries
  • Bristol-Myers Squibb Company, Key Manufacturing Facilities

List of Figures

  • Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2016
  • Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016
  • Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016
  • Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016
  • Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2016
  • Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016
  • Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016
  • Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top